Ayvakit has been recommended by NICE for ASM – an umbrella term that covers aggressive systemic mastocytosis, systemic mastocytosis with an associated haematological neoplasm (SM-AHN), and mast cell ...

The Molecular Glue Drug Development Summit returns to Boston with fresh insights and opportunities! With powerhouse partnerships lighting up the industry—like Biogen & Neomorph, Inc.’s groundbreaking ...

Novo Nordisk has abandoned a drug it licensed from KBP Biosciences last year in a deal valued at up to $1.3 billion after it missed the mark in a chronic kidney disease (CKD) trial.

The 6th RNAi-Based Therapeutics Summit is returning to Boston in January 2025 with fresh insights and perspectives.

Anglo-US contract development and manufacturing organisation (CDMO) Avid Bioservices has agreed a deal to be acquired by ...

Boston, US-based XRHealth is leading the deal, acquiring NeuroReality of the Netherlands for an undisclosed sum, combining their products and expertise in the use of XR and virtual reality software ...

Cassava then released the altered data in a press release and investor deck, which led the SEC to allege that the company and ...

Read Deep Dive: Patients & Partnerships in full pharmaphorum’s digital magazine Deep Dive provides objective, issue-driven ...

CD40 agonists have had mixed results in cancer to date, with Roche discontinuing its selicrelumab candidate after ...

It is all over bar the shouting win for the US election, with Donald Trump set to claim the Presidency, potentially with the ...

GLP-1 agonist Wegovy (semaglutide) brought in DKK 17.3 billion ($2.49 billion) in the period, restoring earlier levels of ...

BEAM-101 is an ex vivo genetic therapy delivered as part of an autologous haematopoietic stem cell transplant (HSCT) after a conditioning chemotherapy regimen to destroy the bone marrow and allow it ...